2024
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke
Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J. Nanotechnology approaches to drug delivery for the treatment of ischemic stroke. Bioactive Materials 2024, 43: 145-161. PMID: 39386225, PMCID: PMC11462157, DOI: 10.1016/j.bioactmat.2024.09.016.Peer-Reviewed Original ResearchBlood-brain barrierClinical translationClinical trialsFDA-approved pharmacotherapiesReview therapeutic agentsIschemic strokeTherapeutic agentsEffective treatment optionDrug deliveryTreatment of ischemic strokePotential clinical translationGlobal public health concernImprove delivery efficiencyTreatment optionsTreatment strategiesIschemic brainPublic health concernStroke pharmacotherapyEngineered nanoparticlesStroke treatment strategiesDelivery efficiencyNanotechnological approachesDrugPharmacotherapyStrokeGlobal pandemic preparedness: learning from the COVID-19 vaccine development and distribution
Agampodi S, Mogeni O, Chandler R, Pansuriya M, Kim J, Excler J. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution. Expert Review Of Vaccines 2024, 23: 761-772. PMID: 39167221, DOI: 10.1080/14760584.2024.2395546.Peer-Reviewed Original ResearchConceptsPandemic vaccine developmentVaccine developmentGlobal health securityField of vaccinologyVaccine deliveryFuture pandemicsTherapeutic agentsVaccineHealth securityCOVID-19 vaccine developmentResponse frameworkPandemic preparednessDistribution of vaccinesStakeholder websitesCOVID-19Adequate fundingVaccine innovationCOVID-19 pandemicPotential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence
Manhapra A, Rosenheck R, Becker W. Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence. 2024, 148-164. DOI: 10.1093/9780197675250.003.0009.Peer-Reviewed Original ResearchLong-term opioid therapyKappa-opioid receptorsChronic painOpioid receptorsKappa-opioid receptor antagonismManagement of comorbid depressionTherapeutic agentsMOR agonismOpioid therapyOpioid taperAntidepressant effectsWorsening painOpioid dependenceSafety profileAgonist actionPoor outcomeClinical trialsAssociated with worsening depressionPainEtiological driversBuprenorphineReceptor affinityComorbid depressionOpioidReceptors
2023
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Original ResearchPsychiatric disordersLysergic acid diethylamideClinical trialsUS Clinical Trials RegistryClinical Trials RegistryPotential therapeutic effectsTrials RegistryTherapeutic effectPotential therapyTherapeutic agentsN-dimethyltryptamineAcid diethylamideLargest causePsychedelic compoundsDisordersPsychotherapeutic approachesSafety concernsTrialsPotential interactive effectsCutting-edge reviewPsychedelic substancesRegistryTherapyNew Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
Shafi S, Challa B, Parwani A, Aung T. New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives. Cutis 2023, 112: e32-e39. PMID: 38091429, DOI: 10.12788/cutis.0911.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLymphocyte-activating gene-3Early phase clinical trialsPrimary treatment failureAggressive skin cancerNew therapeutic agentsICI therapyCheckpoint inhibitorsNovel immunotherapiesMelanoma patientsTreatment failureMetastatic melanomaPredictive biomarkersLong-term benefitsClinical trialsClinical careNew therapiesTherapeutic strategiesAlternative treatmentSkin cancerTherapy outcomeTherapeutic agentsNovel targetNovel therapeuticsPatientsThe Potential of Psychedelics for the Treatment of Episodic Migraine
Schindler E. The Potential of Psychedelics for the Treatment of Episodic Migraine. Current Pain And Headache Reports 2023, 27: 489-495. PMID: 37540398, DOI: 10.1007/s11916-023-01145-y.Peer-Reviewed Original ResearchConceptsEpisodic migrainePotential of psychedelicsWeekly migraine daysPsychedelic drugsMigraine daysPain intensityTransitional treatmentCluster headacheHeadache disordersPreventive effectClinical trialsSingle administrationTherapeutic effectAbortive effectMigrainePsychiatric conditionsReviewThis reviewTherapeutic agentsDrugsAdditional findingsMedicinal usePsychedelicsTreatmentPotential medicinal usePsilocybinCase report: Psychedelic-induced seizures captured by intracranial electrocorticography
Blond B, Schindler E. Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Frontiers In Neurology 2023, 14: 1214969. PMID: 37456653, PMCID: PMC10343433, DOI: 10.3389/fneur.2023.1214969.Peer-Reviewed Original ResearchDrug classesRight temporal lobe epilepsyDrug-induced seizuresRisk of seizuresTemporal lobe epilepsyHistory of epilepsyResponsive neurostimulation systemUnique clinical benefitsSeizure frequencyClinical benefitLobe epilepsyLarge doseDrug dosesDrug useSeizuresClassic psychedelicsIntracranial electrocorticographyNeurostimulation systemTherapeutic agentsAdverse effectsPsychedelic compoundsPsychedelic drug useClinical applicationEpilepsyRiskMitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents
Chen J, Guo X, Li D, Tang H, Gao J, Yu W, Zhu X, Sun Z, Huang Z, Chen L. Mitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents. Metallomics 2023, 15: mfad035. PMID: 37204038, DOI: 10.1093/mtomcs/mfad035.Peer-Reviewed Original ResearchConceptsLoss of mitochondrial membrane potentialIridium complexesDeath of A549 cellsMitochondrial membrane potentialA549 cellsDepletion of cellular ATPElevation of reactive oxygen speciesNSCLC therapeutic agentsMitochondrial eventsCaspase pathwayCancer therapeutic agentsReactive oxygen speciesPotential antitumor effectsCellular ATPDevelopment of antitumor drugsMulticellular tumor spheroid modelAntitumor effectNon-smallTumor spheroid modelTumor growthMembrane potentialIridiumOxygen speciesTherapeutic agentsAntitumor drugsWhat’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
Awada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMDS/AML patientsEarly clinical trialsPotential therapeutic agentAML patientsMultidrug combinationsClinical trialsMyeloid leukemiaMyeloid neoplasmsRational approachSingle agentCurrent managementTherapeutic potentialStandardized guidelinesTherapeutic agentsMutational characteristicsPatientsNeoplasmsLatest findingsGenomic factorsCellular adaptationAgentsHMA resistanceFailureLeukemiaCell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine
León-Martínez D, Lynn T, Abrahams V. Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine. Journal Of Reproductive Immunology 2023, 157: 103945. PMID: 37062109, DOI: 10.1016/j.jri.2023.103945.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Aspirin-triggered lipoxinsODN 2216Pathogenesis of preeclampsiaTLR9-dependent mannerNovel therapeutic approachesTrophoblast cell modelReceptor 9CpG oligodeoxynucleotideTLR9 inhibitorPlacental functionTherapeutic approachesCell-free fetal DNACpG motifsTherapeutic agentsHCQPreeclampsiaHydroxychloroquineFetal DNACell viabilityCffDNAMolecular underpinningsCell modelInhibitionASA
2022
Non-Modulator Therapies Developing a Therapy for Every Cystic Fibrosis Patient
Egan M. Non-Modulator Therapies Developing a Therapy for Every Cystic Fibrosis Patient. Clinics In Chest Medicine 2022, 43: 717-725. PMID: 36344076, DOI: 10.1016/j.ccm.2022.06.011.Peer-Reviewed Original ResearchConceptsModulator therapyCystic fibrosisCystic fibrosis transmembrane conductance regulator (CFTR) modulator therapiesCFTR modulator therapyTreatment of CFCystic fibrosis patientsGenetic-based therapiesMost patientsCF patientsFibrosis patientsTherapyPremature termination codon mutationsTherapeutic agentsPatientsDNA therapyRNA therapyTermination codon mutationsCodon mutationAn update on the diagnosis and treatment of adrenoleukodystrophy
Gujral J, Sethuram S. An update on the diagnosis and treatment of adrenoleukodystrophy. Current Opinion In Endocrinology Diabetes And Obesity 2022, 30: 44-51. PMID: 36373727, DOI: 10.1097/med.0000000000000782.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantTreatment optionsOnly successful treatment optionManagement of patientsStem cell transplantRecommended Uniform Screening PanelSuccessful treatment optionPotential treatment optionUniform Screening PanelTreatment of adrenoleukodystrophyAdrenal insufficiencyCell transplantCerebral adrenoleukodystrophyConsensus guidelinesNeurological changesNovel therapiesEarly diagnosisAnimal modelsAmerican AcademyAdrenoleukodystrophyTherapeutic agentsScreening panelDiagnosisTherapyDiseaseUterine administration of C-X-C motif chemokine ligand 12 increases the pregnancy rates in mice with induced endometriosis
Rosa-E-Silva ACJS, Mamillapalli R, Rosa-E-Silva JC, Ucar A, Schwartz J, Taylor HS. Uterine administration of C-X-C motif chemokine ligand 12 increases the pregnancy rates in mice with induced endometriosis. F&S Science 2022, 4: 65-73. PMID: 36252793, DOI: 10.1016/j.xfss.2022.10.003.Peer-Reviewed Original ResearchConceptsC motif chemokine ligand 12Endometriosis groupPregnancy rateChemokine ligand 12Alpha v beta 3 integrinUterine injectionBeta 3 integrinBMDC recruitmentProgesterone receptorMouse modelBone marrow-derived cell recruitmentHigher cumulative pregnancy rateLigand 12Therapeutic agentsEndometrial receptivity defectsCumulative pregnancy rateEndometrial receptivity markersSham surgery groupBone marrow transplantationLower pregnancy ratesAcademic medical centerPotential therapeutic agentReceptivity markersSurgery groupInduced endometriosisPrimary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy designTumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
Marczyk M, Qing T, O’Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. Npj Breast Cancer 2022, 8: 88. PMID: 35869114, PMCID: PMC9307813, DOI: 10.1038/s41523-022-00449-3.Peer-Reviewed Original ResearchTumor immune microenvironmentImmune microenvironmentTriple-negative breast cancer tissuesTriple-negative breast cancerAfrican AmericansImmune checkpoint inhibitorsTumor mutation burdenNegative breast cancerBreast cancer tissuesImmune-related pathwaysStromal TILsCheckpoint inhibitorsImmune exclusionClinical outcomesPD-L1Self-identified African AmericansCancer patientsImmune infiltrationBreast cancerMutation burdenCancer tissuesPredictive signatureMRNA expressionTherapeutic agentsPatientsmiRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers
Dey A, Yousefiasl S, Kumar A, Moghaddam F, Rahimmanesh I, Samandari M, Jamwal S, Maleki A, Mohammadi A, Rabiee N, Paiva‐Santos A, Tamayol A, Sharifi E, Makvandi P. miRNA‐encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers. Bioengineering & Translational Medicine 2022, 8: e10343. PMID: 36684081, PMCID: PMC9842058, DOI: 10.1002/btm2.10343.Peer-Reviewed Original ResearchAre We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationCD47/SIRPαIntensive induction therapyAvailable therapeutic optionsStem cell transplantationStandard of careAvailable clinical dataTesting of agentsInduction therapyMedian overallRefractory settingAggressive treatmentTim-3Immune checkpointsPreclinical rationaleTherapeutic optionsCell transplantationEfficacy dataClinical dataPatientsMolecular subgroupsTherapeutic agentsSurface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
Luks VL, Mandl H, DiRito J, Barone C, Freedman-Weiss MR, Ricciardi AS, Tietjen GG, Egan ME, Saltzman WM, Stitelman DH. Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells. PLOS ONE 2022, 17: e0266218. PMID: 35385514, PMCID: PMC8986008, DOI: 10.1371/journal.pone.0266218.Peer-Reviewed Original ResearchConceptsTarget-specific antibodiesNanoparticle uptakeSurface conjugationNanoparticle surface modificationSurface of nanoparticlesCellular uptakeSite-specific geneSpecific cellular bindingNanoparticlesIntracellular deliveryEditing reagentsBronchial epithelial cellsSurface modificationCellular targetingCystic fibrosisTherapeutic agentsEpithelial cellsParticle uptakeFeasible strategyGenetic diseasesFirst demonstrationHuman bronchial epithelial cellsKinetics of antibodiesCellular bindingAppropriate antibodiesBrain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery
Zhang S, Peng B, Chen Z, Yu J, Deng G, Bao Y, Ma C, Du F, Sheu WC, Kimberly WT, Simard JM, Coman D, Chen Q, Hyder F, Zhou J, Sheth KN. Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery. Bioactive Materials 2022, 16: 57-65. PMID: 35386312, PMCID: PMC8958421, DOI: 10.1016/j.bioactmat.2022.02.033.Peer-Reviewed Original ResearchDrug deliveryStroke treatmentTherapeutic agentsBetulinic acidNatural nanomaterialsSurface conjugationDrug releaseDrug carriersAntioxidant nanoparticlesEfficient carrierTreatment of strokeEffective pharmacological treatmentCause of deathNanoparticlesPotent therapeutic agentIschemic brainPharmacological treatmentCXCR4 antagonistIntravenous administrationSignificant efficacyIschemic tissueNeuroprotective peptidePotent antioxidantStrokeCarriers
2021
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
Tymon-Rosario J, Adjei NN, Roque DM, Santin AD. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment. Cancers 2021, 13: 6239. PMID: 34944858, PMCID: PMC8699494, DOI: 10.3390/cancers13246239.Peer-Reviewed Original ResearchEpithelial ovarian cancerOvarian cancerClinical dataEpithelial ovarian cancer treatmentTaxane-treated patientsUse of ixabepiloneRefractory ovarian cancerOngoing clinical trialsStandard of careOvarian cancer treatmentClinical trialsRecurrent treatmentTaxane resistanceCurrent standard practiceChemotherapeutic agentsTherapeutic agentsCancerCancer treatmentPutative mechanismsMicrotubular functionTreatmentDrugs partTaxanesCell deathCurrent use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply